Priyanka Saha1,2,3, Praneetha Potiny1, Joseph Rigdon4, Melissa Morello1,5, Catherine Tcheandjieu1,2,5, Anitra Romfh1,5, Susan M Fernandes1,5, Doff B McElhinney1,2,6, Daniel Bernstein1,2, George K Lui1,5, Gary M Shaw7, Erik Ingelsson2,5,8, James R Priest1,2,8,9. 1. Division of Cardiology, Department of Pediatrics (P.S., P.P., M.M., C.T., A.R., S.M.F., D.B.M., D.B., G.K.L., J.R.P.), Stanford University School of Medicine, CA. 2. Stanford Cardiovascular Institute (P.S., C.T., D.B.M., D.B., E.I., J.R.P.), Stanford University School of Medicine, CA. 3. Harvard Medical School, Boston, MA (P.S.). 4. Quantitative Sciences Unit (J.R.), Stanford University School of Medicine, CA. 5. Department of Medicine, Division of Cardiovascular Medicine (M.M., C.T., A.R., S.M.F., G.K.L., E.I.), Stanford University School of Medicine, CA. 6. Department of Cardiothoracic Surgery (D.B.M.), Stanford University School of Medicine, CA. 7. Department of Pediatrics (G.M.S.), Stanford University School of Medicine, CA. 8. Stanford Diabetes Research Center, Stanford University, CA (E.I., J.R.P.). 9. Chan-Zuckerberg BioHub, San Francisco, CA (J.R.P.).
Abstract
BACKGROUND: Although lower-complexity cardiac malformations constitute the majority of adult congenital heart disease (ACHD), the long-term risks of adverse cardiovascular events and relationship with conventional risk factors in this population are poorly understood. We aimed to quantify the risk of adverse cardiovascular events associated with lower-complexity ACHD that is unmeasured by conventional risk factors. METHODS: A multitiered classification algorithm was used to select individuals with lower-complexity ACHD and individuals without ACHD for comparison among >500 000 British adults in the UK Biobank. ACHD diagnoses were subclassified as isolated aortic valve and noncomplex defects. Time-to-event analyses were conducted for the primary end points of fatal or nonfatal acute coronary syndrome, ischemic stroke, heart failure, and atrial fibrillation and a secondary combined end point for major adverse cardiovascular events. Maximum follow-up time for the study period was 22 years with retrospectively and prospectively collected data from the UK Biobank. RESULTS: We identified 2006 individuals with lower-complexity ACHD and 497 983 unexposed individuals in the UK Biobank (median age at enrollment, 58 [interquartile range, 51-63] years). Of the ACHD-exposed group, 59% were male, 51% were current or former smokers, 30% were obese, and 69%, 41%, and 7% were diagnosed or treated for hypertension, hyperlipidemia, and diabetes mellitus, respectively. After adjustment for 12 measured cardiovascular risk factors, ACHD remained strongly associated with the primary end points, with hazard ratios ranging from 2.0 (95% CI, 1.5-2.8; P<0.001) for acute coronary syndrome to 13.0 (95% CI, 9.4-18.1; P<0.001) for heart failure. ACHD-exposed individuals with ≤2 cardiovascular risk factors had a 29% age-adjusted incidence rate of major adverse cardiovascular events, in contrast to 13% in individuals without ACHD with ≥5 risk factors. CONCLUSIONS: Individuals with lower-complexity ACHD had a higher burden of adverse cardiovascular events relative to the general population that was unaccounted for by conventional cardiovascular risk factors. These findings highlight the need for closer surveillance of patients with mild to moderate ACHD and further investigation into management and mechanisms of cardiovascular risk unique to this growing population of high-risk adults.
BACKGROUND: Although lower-complexity cardiac malformations constitute the majority of adult congenital heart disease (ACHD), the long-term risks of adverse cardiovascular events and relationship with conventional risk factors in this population are poorly understood. We aimed to quantify the risk of adverse cardiovascular events associated with lower-complexity ACHD that is unmeasured by conventional risk factors. METHODS: A multitiered classification algorithm was used to select individuals with lower-complexity ACHD and individuals without ACHD for comparison among >500 000 British adults in the UK Biobank. ACHD diagnoses were subclassified as isolated aortic valve and noncomplex defects. Time-to-event analyses were conducted for the primary end points of fatal or nonfatal acute coronary syndrome, ischemic stroke, heart failure, and atrial fibrillation and a secondary combined end point for major adverse cardiovascular events. Maximum follow-up time for the study period was 22 years with retrospectively and prospectively collected data from the UK Biobank. RESULTS: We identified 2006 individuals with lower-complexity ACHD and 497 983 unexposed individuals in the UK Biobank (median age at enrollment, 58 [interquartile range, 51-63] years). Of the ACHD-exposed group, 59% were male, 51% were current or former smokers, 30% were obese, and 69%, 41%, and 7% were diagnosed or treated for hypertension, hyperlipidemia, and diabetes mellitus, respectively. After adjustment for 12 measured cardiovascular risk factors, ACHD remained strongly associated with the primary end points, with hazard ratios ranging from 2.0 (95% CI, 1.5-2.8; P<0.001) for acute coronary syndrome to 13.0 (95% CI, 9.4-18.1; P<0.001) for heart failure. ACHD-exposed individuals with ≤2 cardiovascular risk factors had a 29% age-adjusted incidence rate of major adverse cardiovascular events, in contrast to 13% in individuals without ACHD with ≥5 risk factors. CONCLUSIONS: Individuals with lower-complexity ACHD had a higher burden of adverse cardiovascular events relative to the general population that was unaccounted for by conventional cardiovascular risk factors. These findings highlight the need for closer surveillance of patients with mild to moderate ACHD and further investigation into management and mechanisms of cardiovascular risk unique to this growing population of high-risk adults.
Authors: Maria Fedchenko; Zacharias Mandalenakis; Annika Rosengren; Georg Lappas; Peter Eriksson; Kristofer Skoglund; Mikael Dellborg Journal: Int J Cardiol Date: 2017-07-01 Impact factor: 4.164
Authors: Jouke P Bokma; Ineke Zegstroo; Joey M Kuijpers; Thelma C Konings; Roland R J van Kimmenade; Joost P van Melle; Philippine Kiès; Barbara J M Mulder; Berto J Bouma Journal: Heart Date: 2017-08-28 Impact factor: 5.994
Authors: Fabien Labombarda; Robert Hamilton; Azadeh Shohoudi; Jamil Aboulhosn; Craig S Broberg; Marie A Chaix; Scott Cohen; Stephen Cook; Annie Dore; Susan M Fernandes; Anne Fournier; Joseph Kay; Laurent Macle; Blandine Mondésert; François-Pierre Mongeon; Alexander R Opotowsky; Anna Proietti; Lena Rivard; Jennifer Ting; Bernard Thibault; Ali Zaidi; Paul Khairy Journal: J Am Coll Cardiol Date: 2017-08-15 Impact factor: 24.094
Authors: Cathie Sudlow; John Gallacher; Naomi Allen; Valerie Beral; Paul Burton; John Danesh; Paul Downey; Paul Elliott; Jane Green; Martin Landray; Bette Liu; Paul Matthews; Giok Ong; Jill Pell; Alan Silman; Alan Young; Tim Sprosen; Tim Peakman; Rory Collins Journal: PLoS Med Date: 2015-03-31 Impact factor: 11.069
Authors: Nicolas L Madsen; Bradley S Marino; Jessica G Woo; Reimar W Thomsen; Jørgen Videbœk; Henning Bœkgaard Laursen; Morten Olsen Journal: J Am Heart Assoc Date: 2016-07-08 Impact factor: 5.501
Authors: Sherry L Farr; Scott E Klewer; Wendy N Nembhard; Caroline Alter; Karrie F Downing; Jennifer G Andrews; R Thomas Collins; Jill Glidewell; Argelia Benavides; Anthony Goudie; Tiffany Riehle-Colarusso; Lindsey Overman; Aspen P Riser; Matthew E Oster Journal: Am Heart J Date: 2020-01-09 Impact factor: 5.099